EIT Health Wild Card winner attracts 1 million USD investment from Microsoft M12 and MayfieldiLoF won the EIT Health Wild Card competition in 2019Start-up uses artificial intelligence (AI) and biophotonics to detect neurogenerative biomarkers and optimise the clinical trial selection process for...
This investment will be crucial to our mission of accelerating personalised treatments for patients all around the world. Our platform technology is growing rapidly and is already being deployed with leading hospitals and biotechs around the globe, expediting the discovery and development of new therapeutics for neurogenerative diseases. By 2021, we aim to enrol a large-scale clinical trial as a precise, non-invasive pre-screening tool for Alzheimer’s, bringing us one step closer to our goal of making the patient’s journey much more humane and convenient, while drastically transforming the whole process into a more efficient and flexible experience for the industry.